在B2M缺陷癌症中的抗瘤免疫反应
Davis Y Torrejon1, Mildred Galvez2, Gabriel Abril-Rodriguez1,2
1Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), Los Angeles, California.
Cancer immunology research
|October 6, 2023
概括
失去β-2微球蛋白 (B2M) 会导致对免疫检查点阻塞 (ICB) 的抵抗. 缺乏B2M的瘤仍然可以通过CD4+T细胞和NK细胞对ICB作出反应,这表明了其他免疫激活途径.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症免疫学 癌症免疫学
背景情况:
- β-2微球蛋白 (B2M) 对于瘤抗原的MHC I类呈现至关重要.
- 失去B2M会对免疫检查点阻塞 (ICB) 疗法产生抗性.
- 具有B2M无活化的瘤对ICB表现出反应,需要对替代免疫反应机制进行研究.
研究的目的:
- 为了研究用抗PD-1疗法治疗的B2M无活化瘤中的免疫反应.
- 在没有表面MHC I类的情况下探索抗瘤免疫机制.
- 分析B2M变化的作用在人类黑色素瘤对PD-1封锁的反应中.
主要方法:
- 在三种不同MHC I类表达和抗PD-1敏感性的小鼠癌症模型中,B2M淘汰.
- 对调解抗瘤反应的免疫细胞群 (CD4+ T细胞,NK细胞) 的分析.
- 检查治疗前黑色素瘤活检 (n≈300) 的B2M突变,LOH和副本数量变异.
主要成果:
- 缺乏B2M的MC38和YUMMER2.1模型对由CD4+T细胞和NK细胞介导的抗PD-1和IL2激动剂做出了反应.
- 具有B2M缺乏症的侵略性B16模型对依赖NK细胞的IL2激动剂表现出部分反应.
- 在人类黑色素瘤中,B2M对异性损失 (LOH) 在非响应者中增强,并与激活的NK细胞透率增加有关.
结论:
- 在B2M缺乏的小鼠模型中,CD4+ T细胞和NK细胞激活可以调节对PD-1阻断的反应.
- 部分B2M损失的人类黑色素瘤中激活的NK细胞可以通过减少MHC I类表达来防止瘤脱离.
相关概念视频
Tumor Immunotherapy
544
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
544
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cytotoxic T Cells-mediated Immune Response
955
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
955


